Shares of Insulet Corp. are up nearly 4% today after the diabetes management company said its 2nd-quarter sales rose nearly 60%.
Bedford, Mass.-based Insulet also slashed its losses by 25.5% as it added 536 basis points to its gross profit margin.
"With sales climbing, gross profits increasing and completion of our infrastructure integration with Neighborhood Diabetes, we remain on track to be at or near operating cash flow break even by the end of this year. Further, we continue to make significant progress towards 510(k) clearance of the smaller, lighter next generation OmniPod. Our manufacturing capacity continues to increase and we expect to be poised for launch once clearance is obtained from the US Food and Drug Administration," president & CEO Duane DeSisto said in prepared remarks.